Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuromuscular Junction Membrane Transport Proteins (NMJ Transport Proteins)
- Target
- NMJ Transport Proteins
- Molecular classification
- SNARE proteins, Ion channels, Enzymes, Receptors
01
Overview
Neuromuscular junction membrane transport proteins encompass a diverse set of transmembrane proteins critical for synaptic transmission at the NMJ. These proteins facilitate neurotransmitter release (SNAREs), mediate postsynaptic receptor activation and ion flux (nAChRs, voltage-gated Na+ channels), and regulate neurotransmitter availability via degradation (AChE). Collectively, they ensure rapid, precise, and coordinated communication between motor neurons and skeletal muscle fibers, enabling voluntary movement. Dysfunctional of these proteins can lead to a range of neuromuscular disorders.
- Other names
- NMJ proteinsNeuromuscular junction proteinsProteins of the neuromuscular junctionSynaptic proteins
02
Mechanism of action
Varies depending on the specific protein. Examples include: - Botulinum toxin: Inhibition of SNARE-mediated exocytosis - Acetylcholinesterase inhibitors: Increase acetylcholine levels in the synaptic cleft. - Immunosuppressants: Reduce antibody production in autoimmune disorders
03
Biological functions
Neurotransmitter releaseNeurotransmissionIon transportSignal transductionMuscle contractionSynaptic transmission
04
Disease associations
Myasthenia gravisLambert-Eaton syndromeCongenital myasthenic syndromesNeuromuscular disorders
05
Safety considerations
Acetylcholinesterase inhibitors: Cholinergic crisis (excessive acetylcholine)Botulinum toxin: ParalysisImmunosuppressants: Increased risk of infection, cancer
06
Interacting drugs
Botulinum toxin
3 more in the full profile.
07
Biomarkers
Anti-AChR antibodies (Myasthenia Gravis)Anti-VGCC antibodies (Lambert-Eaton syndrome)MuSK antibodies (Myasthenia Gravis)LRP4 antibodies (Myasthenia Gravis)
Beyond the preview
Go deeper on Neuromuscular Junction Membrane Transport Proteins (NMJ Transport Proteins).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuromuscular Junction Membrane Transport Proteins (NMJ Transport Proteins).